glp 1 houston GLP‑1 Microdosing TrimRX | Weight Loss Clinic

2025: FDA expanded indication oral semaglutide now approved to reduce major cardiovascular events (MACE) in adults with T2DM at high CV risk

Appropriate supplementation, when indicated based on individual assessment rather than routine use, can help address nutritional gaps during tirzepatide therapy

doi: 10.2337/diabetes.48.12.2270 [DOI] [PubMed] [Google Scholar] 130

State Key Laboratory of Drug Research (SKLDR-2023-TT-04 to H.E.X.)

Lose 13.6% of your body weight on average. One daily tablet = comparable results to injectable Wegovy. Eligible patients lost an average of 13.6% of their body weight in a 64-week clinical trial evaluating 25 mg oral semaglutide compared to those on 2.4 mg injectable semaglutide who lost an average of 14.9% of their body weight in a 68-week clinical trial